Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...
South Korea’s Celltrion (Kosdaq: 068270) has announced the US launch of Steqeyma (ustekinumab-stba), a biosimilar to Stelara ...
It is available in both subcutaneous injection and intravenous infusion ... at an 85% discount to the current WAC list price of STELARA to help improve patient access to high-quality biologic ...
Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...
Selarsdi (ustekinumab-aekn; Teva and Alvotech), and Yesintek (ustekinumab-kfce; Biocon Biologics), all biosimilars to Stelara (ustekinumab; Johnson & Johnson) are now available in the US.
The FDA has provisionally determined that all presentations of SELARSDI can be approved as interchangeable to Stelara® (ustekinumab) injection upon expiry of exclusivity on April 30, 2025 ...
J&J's head of immunodermatology Liza O'Dowd said that the "robust results" with its oral IL-23 drug have the potential to ...
Fresenius Kabi, an operating company of Fresenius, and Formycon AG, a leading, independent developer of high-quality ...
Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback